|
The Department of Health
– Abu Dhabi and Abbott unite
to manufacture
pharmaceuticals locally in
Abu Dhabi
(ABU DHABI)
-
During the BIO International
Convention in Boston, USA,
the
Department of Health –
Abu Dhabi (DoH), the
regulator of the healthcare
sector in Abu Dhabi, and
Abbott, a global
healthcare leader, entered a
landmark partnership to
localize the manufacturing
of pharmaceuticals in Abu
Dhabi and advance digital
health solutions. Leveraging
Abu Dhabi’s advanced life
sciences infrastructure,
this milestone reflects the
emirate’s proactive
preparedness to reduce
dependency on imports,
strengthen supply chain
resilience, and foster a
sustainable, self-sufficient
healthcare ecosystem.
H.E. Dr. Noura Al
Ghaithi, Undersecretary of
the Department of Health –
Abu Dhabi, said: “Following
the recent launch of the
Health, Endurance, Longevity
and Medicine (HELM) Cluster
in Abu Dhabi, the emirate
proved to be equipped with a
holistic, integrated
infrastructure that fosters
local manufacturing and R&D,
positioning it as a regional
healthcare gateway and
leader in life sciences. By
integrating our strategic
vision with Abbott’s
expertise, we aim to
accelerate the development
and deployment of innovative
healthcare products and
solutions, reduce
time-to-market, improve
healthcare outcomes, and
ensure that breakthrough
therapies reach patients
more quickly. This approach
positions Abu Dhabi as a
regional leader in fostering
an agile, innovation-driven
healthcare ecosystem that
directly translates
scientific advancements into
tangible benefits for our
community.”
The
strategic collaboration
outlines a comprehensive
plan focusing on four key
pillars, including
localization of Abbott's
pharmaceutical portfolio,
biosimilar development,
digital transformation
through electronic patient
information leaflets, and a
robust education and
workforce development
initiative.
Mazen
Bachir, Regional Director
for Abbott’s established
pharmaceuticals business in
the Gulf, Emerging Markets,
and Levant, said: “Abbott is
proud to announce a
strategic collaboration with
the Department of Health –
Abu Dhabi, aimed at
advancing healthcare
resilience and innovation in
Abu Dhabi. Building on
Abbott’s long-standing
commitment to the UAE’s
healthcare system, this
partnership will focus on
localizing existing
pharmaceutical products and
jointly exploring the
development of biosimilars,
supported by regulatory
alignment. The collaboration
also includes initiatives to
digitize life science
product information through
electronic leaflets in
alignment with the UAE’s
digital health strategy.
Another key component of
this collaboration is the
development of education
programs to build local
capabilities. Additionally,
Abbott and the Department of
Health will evaluate
opportunities for joint
research and development to
strengthen long-term
healthcare sustainability in
the UAE.”
Led by DoH,
a high-level delegation has
embarked on a strategic
mission to the United States
from June 15 to 21, 2025.
The delegation will conduct
over 20 strategic meetings
and visits with public and
private sector leaders
across the U.S., aimed at
knowledge exchange,
investment opportunities and
the signing of new
agreements that accelerate
the adoption of advanced
health solutions.
Representing Abu Dhabi’s
innovation ecosystem, the
delegation includes key
stakeholders such as the Abu
Dhabi Investment Office,
Mubadala BIO, M42, Masdar
City, KEZAD, PureHealth, and
Etihad Cargo, New York
University Abu Dhabi
(NYUAD), Khalifa University,
startAD and Mohamed bin
Zayed University of
Artificial Intelligence
(MBZUAI).
PRINT
THIS ARTICLE
|
